普利製藥(300630.SZ):左氧氟沙星片獲得德國聯邦藥物和醫療器械管理局上市許可
格隆匯 9 月 1日丨普利製藥(300630.SZ)公佈,公司的全資子公司浙江普利藥業有限公司於近日收到德國聯邦藥物和醫療器械管理局(“BfArM”)所簽發的左氧氟沙星片250mg的上市許可。
藥物名稱:左氧氟沙星片;適應症:左氧氟沙星口服制劑可用於治療成年人(≥18歲)由下列細菌的敏感菌株所引起的下列輕、中、重度感染:醫院獲得性肺炎;急性細菌性鼻竇炎;慢性支氣管炎的急性細菌性發作;複雜性皮膚及皮膚結構感染;非複雜性皮膚及皮膚軟組織感染;慢性細菌性前列腺炎;複雜性尿路感染;急性腎盂腎炎;非複雜性尿路感染;吸入性炭疽(暴露後)。劑型:片劑;規格:250mg。
公司長期以來十分重視藥品的國際化註冊申報,堅持藥品雙報的註冊申報方向,研發註冊始終按照國內外高標準進行,研發中心科研整體水平的提升,為產品研發與註冊的成功奠定了良好的基矗同時,公司努力提高藥品的品質化,實現各品種的規模化,不斷拓展海內外銷售市常近日,公司獲得德國BfArM所簽發的上市許可,標誌着普利製藥具備了在德國銷售左氧氟沙星片的資格,將對公司拓展德國市場帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.